Swiss Medtech Innovator Kuros Biosciences Opens U.S. Headquarters
July 25, 2026 |

Swiss Medtech Innovator Kuros Biosciences Opens U.S. Headquarters

Kuros Bioscience US Headquarters

The maker of the MagnetOs bone graft has chosen North Fulton for its combined U.S. headquarters and manufacturing operation — a global life-sciences vote of confidence in the region, with roughly 50 jobs planned over the next three years.

North Fulton has welcomed a global innovator. Kuros Biosciences — the Swiss medical-technology company behind the MagnetOs synthetic bone graft — has celebrated the grand opening of its U.S. headquarters and manufacturing home in Roswell, planting a long-term flag in one of the Southeast’s fastest-rising life-sciences regions.

Kuros is a company on the move. A spin-off of the University of Zurich and ETH Zurich and listed on the SIX Swiss Exchange, it develops advanced biologic technologies that help surgeons heal bone, with its MagnetOs line used in spine and orthopedic procedures across more than 20 markets on five continents. The company reported a 51% year-over-year jump in sales in the first quarter of 2026, and its new North Fulton site brings headquarters leadership and MagnetOs manufacturing together under one roof — with plans to create roughly 50 jobs over the next three years.

For a company weighing where in America to build, the decision speaks to the fundamentals North Fulton is known for: access to the very definition of talent, proximity to Hartsfield-Jackson and global markets, and a business climate in a class of its own. It is Global Reach, Regional Advantage made real — a high-value, advanced-manufacturing investment that strengthens the region’s thriving life-sciences base.

Kuros Bioscience US Headquarters

Kuros joins a growing roster of ambitious, globally minded companies choosing North Fulton as their center of gravity. It is exactly the kind of arrival that shows a region built for what’s next — and one that keeps building forward. Welcome to Roswell, and welcome to North Fulton.

Source: Based on Kuros Biosciences’ announcement and coverage by BIO-TECHNOPARK Schlieren-Zürich and CoStar, plus the company’s Q1 2026 results. Credit and link the original source(s).